Compare HubSpot Inc (HUBS) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Medpace Holdings Inc — how do they compare? HubSpot Inc trades at $229.3 (market cap $11.56B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Medpace Holdings Inc for 14 Days on average.
| HUBS | MEDP | |
|---|---|---|
Market Cap | $11.56B | $16.82B |
Volume | 1,891,287 | 223,093 |
Sector | Technology | Health |
52-Week High | $494.58 | $630.19 |
52-Week Low | $170.39 | $393.42 |
Typical Hold Time | 78 Days | 14 Days |
Enterprise Value | $10.46B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $228.96, up 3.93% with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth, reaching $3.13B in 2025 with net income turning positive at $45.91M. Recent analyst day highlighted AI strategy enhancements and margin expansion targets, while institutional buying and positive earnings beats support investor confidence. Technical indicators show the stock trading near pivot point resistance at $228 with RSI suggesting potential overbought conditions.
Outlook remains positive with 57% analyst buy ratings and $243.65 consensus target, though high P/E of 82.5x demands sustained growth execution. Key risks include AI competition pressure and valuation sensitivity to earnings momentum. The transition to profitability and strong cash flow generation provide fundamental support for continued upside potential.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
